Prescription Medicines
Lefoxin Tab.
- Product Category
- New broad-spectrum antibacterial agent
- Active Ingredients
- levofloxacin hydrate
- Appearance
- White to light yellow film-coated tablets
- Reimbursement Code
- 648100470
01 / 02
1. Composition and Strength
1 tablet
- Active ingredient: Levofloxacin hydrate (KP) ----- 100mg
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: titanium oxide, magnesium stearate, silicon dioxide, sodium starch glycolate, talc, propylene glycol, hydroxypropyl cellulose, hypromellose 2910, D-mannitol
2. Effectiveness
○ Effective bacterial species
Staphylococcus, Streptococcus pyogenes, Streptococcus hemolytic, Enterococcus, Pneumococcus, Peptococcus, Neisseria gonorrhoeae, Escherichia coli, Citrobacter, Shigella, Enterobacter, Serratia, Proteus, Pseudomonas aeruginosa, Haemophilus influenzae, Acinetobacter, Campylobacter, Chlamydia trachomatis
○ Indications
- Complex skin and soft tissue infections
- Chronic bronchitis, diffuse panbronchiolitis, secondary infection of chronic respiratory disease, community-acquired pneumonia, bronchiectasis (in case of infection)
- Acute pyelonephritis, cystitis, prostatitis, gonococcal urethritis, non-gonococcal urethritis, epididymitis
- Bacterial dysentery, enteritis
- Adnexitis, intrauterine infection, Bartholin's adenitis
- Blepharitis, sty, dacryocystitis, tarsal adenitis, corneal ulcer
- Otitis media (excluding preoperative use for chronic cholesteatomatitis media and chronic otitis media that has metastasized to bone), sinusitis, periodontitis, mandibular inflammation
- Cholecystitis, cholangitis
Since fluoroquinolones, including this drug, are associated with serious adverse reactions, it is used for patients who have no other treatment options for acute bacterial sinusitis, chronic bronchitis, acute bacterial exacerbation of chronic obstructive pulmonary disease, uncomplicated urinary tract infection, acute otitis media, and complicated skin and soft tissue infections.
3. Dosage and dosage
○ Usually, adults take 100 mg orally as levofloxacin hydrate, 2-3 times a day. For patients with severe disease or insufficient efficacy, administer this drug at 200 mg once, three times a day.
Increase or decrease appropriately depending on age and symptoms.
4. Precautions for use
1. Warning
1) Serious adverse reactions including tendonitis, tendon rupture, peripheral neuropathy, central nervous system effects, and worsening of myasthenia gravis.
ㆍFluoroquinolones, including this drug, are associated with disorders that appear with the following symptoms and potentially irreversible serious adverse reactions.
- Tendinitis and tendon rupture
- Peripheral neuropathy
- Central nervous system effects
ㆍIf a patient develops such a serious adverse reaction, immediately discontinue this drug and do not administer fluoroquinolones, including this drug.
Fluoroquinolones, including this drug, may worsen muscle weakness in patients with myasthenia gravis. Do not administer to patients with a history of myasthenia gravis.
ㆍFluoroquinolone drugs, including this drug, are associated with serious adverse reactions, so it is used for patients who have no other treatment options for the following indications among the efficacy and effects approved for each individual drug.
- Acute bacterial rhinosinusitis
- Acute bacterial exacerbation of chronic bronchitis and of chronic obstructive pulmonary disease
- Uncomplicated urinary tract infections
- Acute otitis media
2) Among patients who received quinolone antibacterial agents such as levofloxacin, tendon ruptures of the shoulder, hand, and Achilles tendon, which required surgical operation or prolonged the period of disability, were reported. In post-marketing studies, this risk increases further in elderly patients, patients with renal impairment, solid organ transplant patients, patients receiving a daily dose of 1000 mg of levofloxacin, or when used in combination with corticosteroids. Therefore, concurrent administration with corticosteroids should be avoided. If the patient experiences pain, inflammation, or tendon rupture, this drug should be discontinued and corticosteroids should not be used. You should also rest and refrain from exercise until you are definitely diagnosed with tendonitis or tendon rupture. Tendinitis and tendon rupture (especially the Achilles tendon) sometimes occur bilaterally and may occur within the first 48 hours after taking this medicine. It may also occur several months after stopping this medication.
3) Quinolone antibacterial agents have a neuromuscular blocking effect, so symptoms may worsen in patients with myasthenia gravis. In post-marketing surveillance, serious adverse reactions, including death and cases requiring respiratory support, were reported in patients with myasthenia gravis who took quinolone antibacterial agents. (Refer to ‘3. Prudent administration’)
2. Do not administer to the following patients.
1) Patients with a history of hypersensitivity to this drug or quinolone antibacterial agents
2) Patients with a history of tendonitis or tendon rupture caused by this drug or quinolone antibacterial agents
3) Children and growing adolescents under 18 years of age
4) Pregnant women or women who may be pregnant and lactating women
5) Epilepsy patients
3. Administer with caution to the following patients:
1) Patients with severe renal impairment
2) Patients with or suspected to have central nervous system disease such as severe cerebral arteriosclerosis (there is a risk of convulsions).
3) Patients with a history of convulsive disease (there is a risk of convulsions)
4) Patients taking phenylacetic or propionic acid-based non-steroidal anti-inflammatory drugs such as fenbufen or flurbiprofen and theophylline (there is a risk of convulsions).
5) Elderly people
6) Diabetic patients receiving this drug simultaneously with insulin or oral hypoglycemic agents
7) Patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency (hemolytic reaction may occur in rare cases)
8) Myasthenia gravis patients (symptoms may become worse.)
9) Patients with aortic aneurysm or aortic dissection, or a history of aortic aneurysm or aortic dissection, or patients with a family history or risk factors for aortic aneurysm or aortic dissection (e.g. Marval syndrome, etc.)
10) Patients with heart valve regurgitation/failure or a history of heart valve regurgitation/failure, or patients with a family history or risk factors for heart valve regurgitation/failure (e.g. infective endocarditis, etc.)
4. Adverse reactions
1) Shock: Shock may occur in rare cases, so observe thoroughly. If symptoms such as lowered blood pressure, difficulty breathing, or chest tightness appear, immediately stop administration and take appropriate measures.
2) Hypersensitivity reactions: Fatal hypersensitivity reactions and anaphylactic reactions have been reported, and some reactions may be accompanied by cardiovascular collapse, hypotensive shock, seizures, loss of consciousness, numbness, angioedema, airway obstruction, difficulty breathing, hives, itching, rapid heart rate, difficulty swallowing, and other serious skin reactions. In addition, although the causal relationship with drugs is not clear, serious and sometimes fatal hypersensitivity reactions accompanied by symptoms such as hypersensitivity vasculitis have been reported in rare cases in patients who have repeatedly administered quinolone antibiotics, including levofloxacin. If these symptoms appear, discontinue administration. Also, avoid excessive sunlight or artificial ultraviolet rays, and discontinue administration if photosensitivity reaction accompanied by blisters or erythema occurs.
3) Mental nervous system: Occasionally, insomnia, dizziness, headache, rarely tremors, anxiety, depression, psychotic reactions (hallucinations, paranoia, nervousness, delirium, disorientation, attention disorder, nightmares, etc.), nervousness, confusion, convulsions, and very rarely visual and hearing impairment, taste and smell impairment, and auditory hallucinations may occur. As a peripheral nerve disorder, in rare cases, paresthesia, hypoesthesia, sensory disturbance, and weakness have been reported as a result of polyneuropathy of sensory nerves or sensorimotor axons. If neurological symptoms such as pain, burning, numbness, numbness, light touch, pain, temperature, position, or vibration sensation appear, discontinue administration. There are also reports of rare numbness occurring with ofloxacin (see ‘General precautions’).
4) Circulatory system: Sometimes heart rhythm disorders such as palpitations may occur. It has been reported to be associated with QT interval prolongation and, in rare cases, arrhythmia on electrocardiograms, and torsades de pointes has been rarely reported in post-marketing surveillance, so administration is contraindicated in patients with risk factors for torsades de pointes such as hypokalemia, significant bradycardia, and cardiomyopathy.
5) Kidney: Occasionally, BUN and serum creatinine may increase, and in very rare cases, acute renal failure may occur. In addition, although the causal relationship with the drug is not clear, serious and sometimes fatal hypersensitivity reactions accompanied by symptoms such as interstitial nephritis have been reported in rare cases in patients who have been repeatedly administered quinolone antibiotics, including levofloxacin.
6) Liver: Commonly elevated liver enzyme levels (AST/ALT), sometimes acute liver necrosis, acute liver failure, severe hepatitis, liver failure, jaundice, ALP, γ-GTP, and total bilirubin may occur.
7) Blood system: Occasionally, a decrease in white blood cells, a decrease in red blood cells, a decrease in hemoglobin, a decrease in hematocrit, an increase in eosinophils, pancytopenia, anemia, hemolytic anemia (symptoms: hemoglobinuria), thrombocytopenia, and very rarely agranulocytosis may occur. Therefore, observe thoroughly and discontinue administration if abnormalities appear.
8) Digestive system: Occasionally nausea, vomiting, abdominal discomfort, diarrhea, loss of appetite, abdominal pain, abdominal bloating, rarely indigestion, stomatitis, glossitis, thirst, constipation, etc. may occur. In addition, in rare cases, colitis accompanied by bloody stool, such as life-threatening pseudomembranous colitis, may occur. If symptoms suggestive of colitis such as abdominal pain or frequent diarrhea appear, immediately stop administration and take appropriate measures.
9) Musculoskeletal system: Be careful because rhabdomyolysis may occur accompanied by rapid deterioration of renal function, characterized by muscle pain, weakness, elevated CPK, and elevated myoglobin in the blood and urine. In rare cases, tendon diseases such as joint pain and tendinitis, and very rarely, tendon rupture may occur. Muscle weakness may occur, especially in myasthenia gravis patients, as symptoms may worsen, so be careful.
10) Skin: Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (Lyell syndrome), eosinophilia, and drug reaction with systemic symptoms (DRESS) may occur, so observe thoroughly and if abnormalities appear, stop administration and take appropriate measures.
11) Respiratory system: Be cautious as interstitial pneumonia or allergic pneumonia accompanied by fever, cough, difficulty breathing, abnormal chest
12) Blood sugar disorders (hyperglycemia or hypoglycemia) have been reported in diabetic patients taking oral hypoglycemic agents or insulin. In such cases, discontinue administration and take appropriate measures.
13) Others
In phase 3 clinical trials conducted in North America, adverse reactions related to this drug occurred in 6.7% of subjects. 4.1% of subjects discontinued treatment with this drug due to adverse events. The overall incidence rate and types and distribution of adverse events were similar when 750 mg was administered once a day, 250 mg once a day, and 500 mg once a day or twice a day. Among the subjects who received this drug in this clinical trial, adverse drug events judged to be related to this drug are as follows. : Nausea 1.5%, diarrhea 1.2%, vaginitis 0.5%, insomnia 0.4%, abdominal pain 0.4%, flatulence 0.2%, itching 0.2%, dizziness 0.3%, rash 0.3%, indigestion 0.3%, genital candidiasis 0.1%, candidiasis 0.2%, dysgeusia 0.2%, vomiting 0.3%, constipation 0.1%, fungal infection 0.1%, genital itching 0.1%, headache 0.2%, neurosis 0.1%, erythematous rash 0.1%, urticaria 0.1%, loss of appetite 0.1%, drowsiness 0.1%, excitement 0.1%, dry mouth 0.2%, tremor 0.1%, allergic reaction. 0.1%
14) Aortic aneurysm or aortic dissection, heart valve regurgitation/failure: Aortic aneurysm, aortic dissection, or heart valve regurgitation/failure may occur. If an abnormality is found, appropriate measures must be taken.
15) Endocrine system: Syndrome of abnormal secretion of antidiuretic hormone (SIADH)
5. General precautions
1) When using this drug, it is advisable to check susceptibility and administer only the minimum period necessary for treatment to prevent the development of resistant bacteria.
2) Fluoroquinolones, including this drug, are associated with an increased risk of seizures (convulsions), increased intracranial pressure (pseudoencephaloma), dizziness, and tremors. Like other fluoroquinolones, administration of this drug is known to cause seizures or lower the seizure threshold. Patients with risk factors for epilepsy and central nervous system disease (e.g., lowered convulsive threshold, history of convulsions, decreased cerebral blood flow, changes in brain structure, or stroke) may experience adverse central nervous system reactions, and should be made aware of this and administered this drug only when it is judged that the therapeutic benefits outweigh the risks. Cases of status epilepticus have been reported with other fluoroquinolone antibacterial agents. If seizures occur, this medication should be discontinued.
3) Photosensitivity reaction due to this drug is a very rare reaction, but in order to prevent photosensitivity reaction, patients should avoid exposing themselves to unnecessarily strong sunlight or artificial ultraviolet rays (e.g. solar lamps, solariums, etc.), and should stop taking the drug if symptoms suspicious of photosensitivity reaction such as rash occur.
4) Effects on driving or operating machinery
Undesirable effects such as dizziness, drowsiness, and visual disturbances may impair a patient's ability to concentrate and cope, which may affect tasks such as driving a car or operating machinery.
5) In most cases of severe pneumococcal pneumonia, this drug may not be an appropriate treatment. And nosocomial infections caused by P. aeruginosa require concomitant administration with other drugs.
6) Pseudomembranous colitis, which can range from mild to life-threatening, has been reported with most antibacterial agents, including this drug. Therefore, patients who have diarrhea after taking any antibacterial agent should be cautious. Since toxic substances produced by Clostridium difficile are known to be the primary cause, when pseudomembranous colitis is suspected, administration of this drug should be stopped immediately, and the patient should be treated with auxiliary measures ± special treatment (for example, oral vancomycin, etc.) without delay. In this clinical condition, agents that inhibit intestinal peristalsis should be contraindicated.
7) In patients receiving fluoroquinolones, including drugs for peripheral neuropathy, paresthesia, hypoesthesia, sensory impairment, and weakness were reported as a result of polyneuropathy of the sensory nerves or sensorimotor axons. Symptoms may appear quickly after starting treatment with this drug and may be irreversible. Patients who experience symptoms of neuropathy accompanied by changes in burning, tingling, numbness, light touch, pain, temperature, position, or vibration sensations should discontinue taking this drug to prevent progression to an irreversible condition.
8) Visual impairment
If visual impairment occurs due to administration of this drug, an ophthalmologist should be consulted immediately. Several observational studies have reported a slight increase in the risk of retinal detachment when fluoroquinolones were administered. However, the causal relationship has not been clearly established.
9) Aortic aneurysm or aortic dissection may occur. Patients should be instructed to observe carefully and consult a doctor immediately if they experience symptoms of pain in the abdomen, chest, or back. It should be used in patients with aortic aneurysm or aortic dissection, past medical history, family history, or risk factors for aortic aneurysm or aortic dissection, only if alternative treatments are not available. If necessary, imaging evaluation should be considered.
10) Fluoroquinolones, including this drug, may cause serious adverse reactions such as tendonitis, tendon rupture, musculoskeletal disorders, mental disorders, and nervous system disorders including sensory abnormalities, which may last for more than 30 days or be permanent.
11) Fluoroquinolone antibacterial agents may cause blood sugar disorders, including hyperglycemia or hypoglycemia, in diabetic patients taking oral hypoglycemic agents or insulin concomitantly. Therefore, blood glucose in these patients must be carefully monitored. Cases of severe hypoglycemia resulting in coma or death have been reported. If hypoglycemia occurs in a patient being treated with this drug, treatment with this drug should be discontinued and appropriate treatment should be initiated immediately.
12) Severe adverse skin reactions (SCAR), including toxic epidermal necrolysis (TEN, also known as Lyell syndrome), Stevens-Johnson syndrome (SJS), and drug reaction with eosinophilia and systemic symptoms (DRESS), which can be life-threatening or fatal, have been reported. Patients should be advised of signs/symptoms of severe skin reactions at the time of prescription and patients should be monitored closely. If signs/symptoms indicating such a reaction develop, use of this drug should be discontinued immediately and alternative treatment should be considered. If a patient develops a serious reaction such as SJS, TEN, or DRESS when using this drug, treatment with this drug should not be initiated at any time.
13) Heart valve regurgitation/failure may occur. Patients should be instructed to observe carefully and consult a doctor immediately if they experience symptoms of pain in the abdomen, chest, etc. For patients at risk of heart valve regurgitation/failure, it should be used only when alternative treatments are not available. Patients should seek immediate medical attention if they develop acute shortness of breath, develop new palpitations, or develop abdominal or lower extremity swelling.
14) In an in vitro model that reproduced human blood concentrations in culture medium, administration of 500 mg once a day was found to inhibit the emergence of resistant bacteria of pneumococci and Escherichia coli more than administration of 100 mg three times a day.
6. Interaction
1) Co-administration with quinolone antibacterial agents, including this drug, and non-steroidal anti-inflammatory drugs (e.g. phenylacetic acid or propionic acid such as fenbufen or flurbiprofen) may increase the risk of central nervous stimulation and convulsive seizures, so administer with caution.
2) Combination use with antacids containing aluminum or magnesium, sucralfate, iron-containing preparations, calcium-containing preparations, or multivitamin preparations containing zinc or iron may reduce absorption and reduce effectiveness, so it is advisable not to use this medicine within 2 hours before or after administration.
3) It has been reported that quinolone antibacterial agents increase the blood concentration of theophylline and enhance its action when administered in combination with theophylline, so when used together, theophylline should be administered with caution, such as reducing the amount of theophylline.
4) There are reports that this drug competes with oral anticoagulants such as warfarin at the protein binding site and enhances the action of the anticoagulant, causing bleeding and prolongation of the prothrombin time. Therefore, the dose of the anticoagulant should be reduced, and appropriate hematological monitoring is required when used together.
5) When this drug is administered in combination with cyclosporine, the half-life of cyclosporine increases by 33%, but dose adjustment is not necessary.
6) Probenecid and cimetidine
Probenecid and cimetidine had a statistically significant effect on drug disappearance. The application rate of this drug was reduced by 24% for cimetidine and 34% for probenecid. This is because both drugs have the ability to block renal tubular excretion of this drug. Although these results are not believed to have any immediate clinical significance, this drug should be administered with caution, especially when coadministered with drugs that affect renal tubular excretion, such as probenecid or cimetidine, in patients with renal impairment. Probenecid may reduce the effectiveness of this drug in treating urinary tract infections by inhibiting its ductal secretion.
7) Antidiabetic agent: When taken together with quinolone antibacterial agents, blood sugar disorders (hyperglycemia or hypoglycemia) have been reported, so blood sugar levels must be carefully monitored when administered together.
7. Administration to pregnant and lactating women
1) There were no particular problems in the reproductive toxicity study in animals. However, due to the lack of human research data and the experimental risk of quinolone antibacterial agents damaging the cartilage that supports the weight of growing organisms, this drug is not administered to pregnant women or women who may become pregnant.
2) It is known that ofloxacin, which is structurally similar to this drug, passes into breast milk, so stop breastfeeding while taking this drug.
8. Administration to children
Quinolone antibacterial agents, including this drug, cause arthropathy and osteochondrosis in some young animal species. It is not administered to children and growing adolescents under the age of 18 because its safety has not been established.
9. Administration to elderly people
1) This drug is mainly excreted through the kidneys. Elderly patients often have reduced renal function, so there is a risk that high blood levels will persist and adverse reactions are likely to occur. Therefore, administer with caution, paying attention to the dosage and administration interval.
2) In post-marketing surveillance, severe/sometimes fatal hepatotoxicity was reported in elderly patients over 65 years of age. If a patient develops signs or symptoms of hepatitis, immediately discontinue administration of this drug.
3) According to epidemiological studies, the incidence of aortic aneurysm or aortic dissection increased within 2 months after using fluoroquinolone antibacterial agents, especially in the elderly.
10. Treatment in case of overdose
In animal experiments using mice, rats, dogs, and monkeys, administration of a single high dose of oral preparations of this drug resulted in central nervous system symptoms such as incoordination, drooping eyelids, decreased motor activity, dyspnea, collapse, tremors, and convulsions, as well as prolongation of the QT interval. In case of overdose, gastric lavage should be performed, the patient should be observed carefully, appropriate fluid replacement should be provided, and electrocardiogram monitoring is necessary due to the possibility of QT interval prolongation. This drug is not effectively removed through hemodialysis or peritoneal dialysis.
11. Others
There are reports that joint abnormalities occurred in animal experiments (young dogs, young adult dogs, and young rats).
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle, 100 tablets/bottle
7. Expiration date
36 months from date of manufacture
1 tablet
- Active ingredient: Levofloxacin hydrate (KP) ----- 100mg
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: titanium oxide, magnesium stearate, silicon dioxide, sodium starch glycolate, talc, propylene glycol, hydroxypropyl cellulose, hypromellose 2910, D-mannitol
2. Effectiveness
○ Effective bacterial species
Staphylococcus, Streptococcus pyogenes, Streptococcus hemolytic, Enterococcus, Pneumococcus, Peptococcus, Neisseria gonorrhoeae, Escherichia coli, Citrobacter, Shigella, Enterobacter, Serratia, Proteus, Pseudomonas aeruginosa, Haemophilus influenzae, Acinetobacter, Campylobacter, Chlamydia trachomatis
○ Indications
- Complex skin and soft tissue infections
- Chronic bronchitis, diffuse panbronchiolitis, secondary infection of chronic respiratory disease, community-acquired pneumonia, bronchiectasis (in case of infection)
- Acute pyelonephritis, cystitis, prostatitis, gonococcal urethritis, non-gonococcal urethritis, epididymitis
- Bacterial dysentery, enteritis
- Adnexitis, intrauterine infection, Bartholin's adenitis
- Blepharitis, sty, dacryocystitis, tarsal adenitis, corneal ulcer
- Otitis media (excluding preoperative use for chronic cholesteatomatitis media and chronic otitis media that has metastasized to bone), sinusitis, periodontitis, mandibular inflammation
- Cholecystitis, cholangitis
Since fluoroquinolones, including this drug, are associated with serious adverse reactions, it is used for patients who have no other treatment options for acute bacterial sinusitis, chronic bronchitis, acute bacterial exacerbation of chronic obstructive pulmonary disease, uncomplicated urinary tract infection, acute otitis media, and complicated skin and soft tissue infections.
3. Dosage and dosage
○ Usually, adults take 100 mg orally as levofloxacin hydrate, 2-3 times a day. For patients with severe disease or insufficient efficacy, administer this drug at 200 mg once, three times a day.
Increase or decrease appropriately depending on age and symptoms.
4. Precautions for use
1. Warning
1) Serious adverse reactions including tendonitis, tendon rupture, peripheral neuropathy, central nervous system effects, and worsening of myasthenia gravis.
ㆍFluoroquinolones, including this drug, are associated with disorders that appear with the following symptoms and potentially irreversible serious adverse reactions.
- Tendinitis and tendon rupture
- Peripheral neuropathy
- Central nervous system effects
ㆍIf a patient develops such a serious adverse reaction, immediately discontinue this drug and do not administer fluoroquinolones, including this drug.
Fluoroquinolones, including this drug, may worsen muscle weakness in patients with myasthenia gravis. Do not administer to patients with a history of myasthenia gravis.
ㆍFluoroquinolone drugs, including this drug, are associated with serious adverse reactions, so it is used for patients who have no other treatment options for the following indications among the efficacy and effects approved for each individual drug.
- Acute bacterial rhinosinusitis
- Acute bacterial exacerbation of chronic bronchitis and of chronic obstructive pulmonary disease
- Uncomplicated urinary tract infections
- Acute otitis media
2) Among patients who received quinolone antibacterial agents such as levofloxacin, tendon ruptures of the shoulder, hand, and Achilles tendon, which required surgical operation or prolonged the period of disability, were reported. In post-marketing studies, this risk increases further in elderly patients, patients with renal impairment, solid organ transplant patients, patients receiving a daily dose of 1000 mg of levofloxacin, or when used in combination with corticosteroids. Therefore, concurrent administration with corticosteroids should be avoided. If the patient experiences pain, inflammation, or tendon rupture, this drug should be discontinued and corticosteroids should not be used. You should also rest and refrain from exercise until you are definitely diagnosed with tendonitis or tendon rupture. Tendinitis and tendon rupture (especially the Achilles tendon) sometimes occur bilaterally and may occur within the first 48 hours after taking this medicine. It may also occur several months after stopping this medication.
3) Quinolone antibacterial agents have a neuromuscular blocking effect, so symptoms may worsen in patients with myasthenia gravis. In post-marketing surveillance, serious adverse reactions, including death and cases requiring respiratory support, were reported in patients with myasthenia gravis who took quinolone antibacterial agents. (Refer to ‘3. Prudent administration’)
2. Do not administer to the following patients.
1) Patients with a history of hypersensitivity to this drug or quinolone antibacterial agents
2) Patients with a history of tendonitis or tendon rupture caused by this drug or quinolone antibacterial agents
3) Children and growing adolescents under 18 years of age
4) Pregnant women or women who may be pregnant and lactating women
5) Epilepsy patients
3. Administer with caution to the following patients:
1) Patients with severe renal impairment
2) Patients with or suspected to have central nervous system disease such as severe cerebral arteriosclerosis (there is a risk of convulsions).
3) Patients with a history of convulsive disease (there is a risk of convulsions)
4) Patients taking phenylacetic or propionic acid-based non-steroidal anti-inflammatory drugs such as fenbufen or flurbiprofen and theophylline (there is a risk of convulsions).
5) Elderly people
6) Diabetic patients receiving this drug simultaneously with insulin or oral hypoglycemic agents
7) Patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency (hemolytic reaction may occur in rare cases)
8) Myasthenia gravis patients (symptoms may become worse.)
9) Patients with aortic aneurysm or aortic dissection, or a history of aortic aneurysm or aortic dissection, or patients with a family history or risk factors for aortic aneurysm or aortic dissection (e.g. Marval syndrome, etc.)
10) Patients with heart valve regurgitation/failure or a history of heart valve regurgitation/failure, or patients with a family history or risk factors for heart valve regurgitation/failure (e.g. infective endocarditis, etc.)
4. Adverse reactions
1) Shock: Shock may occur in rare cases, so observe thoroughly. If symptoms such as lowered blood pressure, difficulty breathing, or chest tightness appear, immediately stop administration and take appropriate measures.
2) Hypersensitivity reactions: Fatal hypersensitivity reactions and anaphylactic reactions have been reported, and some reactions may be accompanied by cardiovascular collapse, hypotensive shock, seizures, loss of consciousness, numbness, angioedema, airway obstruction, difficulty breathing, hives, itching, rapid heart rate, difficulty swallowing, and other serious skin reactions. In addition, although the causal relationship with drugs is not clear, serious and sometimes fatal hypersensitivity reactions accompanied by symptoms such as hypersensitivity vasculitis have been reported in rare cases in patients who have repeatedly administered quinolone antibiotics, including levofloxacin. If these symptoms appear, discontinue administration. Also, avoid excessive sunlight or artificial ultraviolet rays, and discontinue administration if photosensitivity reaction accompanied by blisters or erythema occurs.
3) Mental nervous system: Occasionally, insomnia, dizziness, headache, rarely tremors, anxiety, depression, psychotic reactions (hallucinations, paranoia, nervousness, delirium, disorientation, attention disorder, nightmares, etc.), nervousness, confusion, convulsions, and very rarely visual and hearing impairment, taste and smell impairment, and auditory hallucinations may occur. As a peripheral nerve disorder, in rare cases, paresthesia, hypoesthesia, sensory disturbance, and weakness have been reported as a result of polyneuropathy of sensory nerves or sensorimotor axons. If neurological symptoms such as pain, burning, numbness, numbness, light touch, pain, temperature, position, or vibration sensation appear, discontinue administration. There are also reports of rare numbness occurring with ofloxacin (see ‘General precautions’).
4) Circulatory system: Sometimes heart rhythm disorders such as palpitations may occur. It has been reported to be associated with QT interval prolongation and, in rare cases, arrhythmia on electrocardiograms, and torsades de pointes has been rarely reported in post-marketing surveillance, so administration is contraindicated in patients with risk factors for torsades de pointes such as hypokalemia, significant bradycardia, and cardiomyopathy.
5) Kidney: Occasionally, BUN and serum creatinine may increase, and in very rare cases, acute renal failure may occur. In addition, although the causal relationship with the drug is not clear, serious and sometimes fatal hypersensitivity reactions accompanied by symptoms such as interstitial nephritis have been reported in rare cases in patients who have been repeatedly administered quinolone antibiotics, including levofloxacin.
6) Liver: Commonly elevated liver enzyme levels (AST/ALT), sometimes acute liver necrosis, acute liver failure, severe hepatitis, liver failure, jaundice, ALP, γ-GTP, and total bilirubin may occur.
7) Blood system: Occasionally, a decrease in white blood cells, a decrease in red blood cells, a decrease in hemoglobin, a decrease in hematocrit, an increase in eosinophils, pancytopenia, anemia, hemolytic anemia (symptoms: hemoglobinuria), thrombocytopenia, and very rarely agranulocytosis may occur. Therefore, observe thoroughly and discontinue administration if abnormalities appear.
8) Digestive system: Occasionally nausea, vomiting, abdominal discomfort, diarrhea, loss of appetite, abdominal pain, abdominal bloating, rarely indigestion, stomatitis, glossitis, thirst, constipation, etc. may occur. In addition, in rare cases, colitis accompanied by bloody stool, such as life-threatening pseudomembranous colitis, may occur. If symptoms suggestive of colitis such as abdominal pain or frequent diarrhea appear, immediately stop administration and take appropriate measures.
9) Musculoskeletal system: Be careful because rhabdomyolysis may occur accompanied by rapid deterioration of renal function, characterized by muscle pain, weakness, elevated CPK, and elevated myoglobin in the blood and urine. In rare cases, tendon diseases such as joint pain and tendinitis, and very rarely, tendon rupture may occur. Muscle weakness may occur, especially in myasthenia gravis patients, as symptoms may worsen, so be careful.
10) Skin: Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (Lyell syndrome), eosinophilia, and drug reaction with systemic symptoms (DRESS) may occur, so observe thoroughly and if abnormalities appear, stop administration and take appropriate measures.
11) Respiratory system: Be cautious as interstitial pneumonia or allergic pneumonia accompanied by fever, cough, difficulty breathing, abnormal chest
12) Blood sugar disorders (hyperglycemia or hypoglycemia) have been reported in diabetic patients taking oral hypoglycemic agents or insulin. In such cases, discontinue administration and take appropriate measures.
13) Others
In phase 3 clinical trials conducted in North America, adverse reactions related to this drug occurred in 6.7% of subjects. 4.1% of subjects discontinued treatment with this drug due to adverse events. The overall incidence rate and types and distribution of adverse events were similar when 750 mg was administered once a day, 250 mg once a day, and 500 mg once a day or twice a day. Among the subjects who received this drug in this clinical trial, adverse drug events judged to be related to this drug are as follows. : Nausea 1.5%, diarrhea 1.2%, vaginitis 0.5%, insomnia 0.4%, abdominal pain 0.4%, flatulence 0.2%, itching 0.2%, dizziness 0.3%, rash 0.3%, indigestion 0.3%, genital candidiasis 0.1%, candidiasis 0.2%, dysgeusia 0.2%, vomiting 0.3%, constipation 0.1%, fungal infection 0.1%, genital itching 0.1%, headache 0.2%, neurosis 0.1%, erythematous rash 0.1%, urticaria 0.1%, loss of appetite 0.1%, drowsiness 0.1%, excitement 0.1%, dry mouth 0.2%, tremor 0.1%, allergic reaction. 0.1%
14) Aortic aneurysm or aortic dissection, heart valve regurgitation/failure: Aortic aneurysm, aortic dissection, or heart valve regurgitation/failure may occur. If an abnormality is found, appropriate measures must be taken.
15) Endocrine system: Syndrome of abnormal secretion of antidiuretic hormone (SIADH)
5. General precautions
1) When using this drug, it is advisable to check susceptibility and administer only the minimum period necessary for treatment to prevent the development of resistant bacteria.
2) Fluoroquinolones, including this drug, are associated with an increased risk of seizures (convulsions), increased intracranial pressure (pseudoencephaloma), dizziness, and tremors. Like other fluoroquinolones, administration of this drug is known to cause seizures or lower the seizure threshold. Patients with risk factors for epilepsy and central nervous system disease (e.g., lowered convulsive threshold, history of convulsions, decreased cerebral blood flow, changes in brain structure, or stroke) may experience adverse central nervous system reactions, and should be made aware of this and administered this drug only when it is judged that the therapeutic benefits outweigh the risks. Cases of status epilepticus have been reported with other fluoroquinolone antibacterial agents. If seizures occur, this medication should be discontinued.
3) Photosensitivity reaction due to this drug is a very rare reaction, but in order to prevent photosensitivity reaction, patients should avoid exposing themselves to unnecessarily strong sunlight or artificial ultraviolet rays (e.g. solar lamps, solariums, etc.), and should stop taking the drug if symptoms suspicious of photosensitivity reaction such as rash occur.
4) Effects on driving or operating machinery
Undesirable effects such as dizziness, drowsiness, and visual disturbances may impair a patient's ability to concentrate and cope, which may affect tasks such as driving a car or operating machinery.
5) In most cases of severe pneumococcal pneumonia, this drug may not be an appropriate treatment. And nosocomial infections caused by P. aeruginosa require concomitant administration with other drugs.
6) Pseudomembranous colitis, which can range from mild to life-threatening, has been reported with most antibacterial agents, including this drug. Therefore, patients who have diarrhea after taking any antibacterial agent should be cautious. Since toxic substances produced by Clostridium difficile are known to be the primary cause, when pseudomembranous colitis is suspected, administration of this drug should be stopped immediately, and the patient should be treated with auxiliary measures ± special treatment (for example, oral vancomycin, etc.) without delay. In this clinical condition, agents that inhibit intestinal peristalsis should be contraindicated.
7) In patients receiving fluoroquinolones, including drugs for peripheral neuropathy, paresthesia, hypoesthesia, sensory impairment, and weakness were reported as a result of polyneuropathy of the sensory nerves or sensorimotor axons. Symptoms may appear quickly after starting treatment with this drug and may be irreversible. Patients who experience symptoms of neuropathy accompanied by changes in burning, tingling, numbness, light touch, pain, temperature, position, or vibration sensations should discontinue taking this drug to prevent progression to an irreversible condition.
8) Visual impairment
If visual impairment occurs due to administration of this drug, an ophthalmologist should be consulted immediately. Several observational studies have reported a slight increase in the risk of retinal detachment when fluoroquinolones were administered. However, the causal relationship has not been clearly established.
9) Aortic aneurysm or aortic dissection may occur. Patients should be instructed to observe carefully and consult a doctor immediately if they experience symptoms of pain in the abdomen, chest, or back. It should be used in patients with aortic aneurysm or aortic dissection, past medical history, family history, or risk factors for aortic aneurysm or aortic dissection, only if alternative treatments are not available. If necessary, imaging evaluation should be considered.
10) Fluoroquinolones, including this drug, may cause serious adverse reactions such as tendonitis, tendon rupture, musculoskeletal disorders, mental disorders, and nervous system disorders including sensory abnormalities, which may last for more than 30 days or be permanent.
11) Fluoroquinolone antibacterial agents may cause blood sugar disorders, including hyperglycemia or hypoglycemia, in diabetic patients taking oral hypoglycemic agents or insulin concomitantly. Therefore, blood glucose in these patients must be carefully monitored. Cases of severe hypoglycemia resulting in coma or death have been reported. If hypoglycemia occurs in a patient being treated with this drug, treatment with this drug should be discontinued and appropriate treatment should be initiated immediately.
12) Severe adverse skin reactions (SCAR), including toxic epidermal necrolysis (TEN, also known as Lyell syndrome), Stevens-Johnson syndrome (SJS), and drug reaction with eosinophilia and systemic symptoms (DRESS), which can be life-threatening or fatal, have been reported. Patients should be advised of signs/symptoms of severe skin reactions at the time of prescription and patients should be monitored closely. If signs/symptoms indicating such a reaction develop, use of this drug should be discontinued immediately and alternative treatment should be considered. If a patient develops a serious reaction such as SJS, TEN, or DRESS when using this drug, treatment with this drug should not be initiated at any time.
13) Heart valve regurgitation/failure may occur. Patients should be instructed to observe carefully and consult a doctor immediately if they experience symptoms of pain in the abdomen, chest, etc. For patients at risk of heart valve regurgitation/failure, it should be used only when alternative treatments are not available. Patients should seek immediate medical attention if they develop acute shortness of breath, develop new palpitations, or develop abdominal or lower extremity swelling.
14) In an in vitro model that reproduced human blood concentrations in culture medium, administration of 500 mg once a day was found to inhibit the emergence of resistant bacteria of pneumococci and Escherichia coli more than administration of 100 mg three times a day.
6. Interaction
1) Co-administration with quinolone antibacterial agents, including this drug, and non-steroidal anti-inflammatory drugs (e.g. phenylacetic acid or propionic acid such as fenbufen or flurbiprofen) may increase the risk of central nervous stimulation and convulsive seizures, so administer with caution.
2) Combination use with antacids containing aluminum or magnesium, sucralfate, iron-containing preparations, calcium-containing preparations, or multivitamin preparations containing zinc or iron may reduce absorption and reduce effectiveness, so it is advisable not to use this medicine within 2 hours before or after administration.
3) It has been reported that quinolone antibacterial agents increase the blood concentration of theophylline and enhance its action when administered in combination with theophylline, so when used together, theophylline should be administered with caution, such as reducing the amount of theophylline.
4) There are reports that this drug competes with oral anticoagulants such as warfarin at the protein binding site and enhances the action of the anticoagulant, causing bleeding and prolongation of the prothrombin time. Therefore, the dose of the anticoagulant should be reduced, and appropriate hematological monitoring is required when used together.
5) When this drug is administered in combination with cyclosporine, the half-life of cyclosporine increases by 33%, but dose adjustment is not necessary.
6) Probenecid and cimetidine
Probenecid and cimetidine had a statistically significant effect on drug disappearance. The application rate of this drug was reduced by 24% for cimetidine and 34% for probenecid. This is because both drugs have the ability to block renal tubular excretion of this drug. Although these results are not believed to have any immediate clinical significance, this drug should be administered with caution, especially when coadministered with drugs that affect renal tubular excretion, such as probenecid or cimetidine, in patients with renal impairment. Probenecid may reduce the effectiveness of this drug in treating urinary tract infections by inhibiting its ductal secretion.
7) Antidiabetic agent: When taken together with quinolone antibacterial agents, blood sugar disorders (hyperglycemia or hypoglycemia) have been reported, so blood sugar levels must be carefully monitored when administered together.
7. Administration to pregnant and lactating women
1) There were no particular problems in the reproductive toxicity study in animals. However, due to the lack of human research data and the experimental risk of quinolone antibacterial agents damaging the cartilage that supports the weight of growing organisms, this drug is not administered to pregnant women or women who may become pregnant.
2) It is known that ofloxacin, which is structurally similar to this drug, passes into breast milk, so stop breastfeeding while taking this drug.
8. Administration to children
Quinolone antibacterial agents, including this drug, cause arthropathy and osteochondrosis in some young animal species. It is not administered to children and growing adolescents under the age of 18 because its safety has not been established.
9. Administration to elderly people
1) This drug is mainly excreted through the kidneys. Elderly patients often have reduced renal function, so there is a risk that high blood levels will persist and adverse reactions are likely to occur. Therefore, administer with caution, paying attention to the dosage and administration interval.
2) In post-marketing surveillance, severe/sometimes fatal hepatotoxicity was reported in elderly patients over 65 years of age. If a patient develops signs or symptoms of hepatitis, immediately discontinue administration of this drug.
3) According to epidemiological studies, the incidence of aortic aneurysm or aortic dissection increased within 2 months after using fluoroquinolone antibacterial agents, especially in the elderly.
10. Treatment in case of overdose
In animal experiments using mice, rats, dogs, and monkeys, administration of a single high dose of oral preparations of this drug resulted in central nervous system symptoms such as incoordination, drooping eyelids, decreased motor activity, dyspnea, collapse, tremors, and convulsions, as well as prolongation of the QT interval. In case of overdose, gastric lavage should be performed, the patient should be observed carefully, appropriate fluid replacement should be provided, and electrocardiogram monitoring is necessary due to the possibility of QT interval prolongation. This drug is not effectively removed through hemodialysis or peritoneal dialysis.
11. Others
There are reports that joint abnormalities occurred in animal experiments (young dogs, young adult dogs, and young rats).
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle, 100 tablets/bottle
7. Expiration date
36 months from date of manufacture
Product Updates
Total 13items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 13 | Lefoxin Tab. | Precautions for use | 2026.03.23 | PDF0015_199806978_Lepoxin tablet_Precautions for use.pdf |
| 12 | Lefoxin Tab. | Precautions for use | 2026.02.03 | PDF0015_199806978_ Repoxin tablet_ Precautions for use.pdf |
| 11 | Lefoxin Tab. | Precautions for use | 2025.08.11 | PDF199806978_Lepoxin tablet_Precautions for use.pdf |
| 10 | Lefoxin Tab. | Precautions for use | 2022.11.29 | Levoxin Tablet (Levofloxacin Hydrate) Change Plan + Change Comparison Table.pdfFile under review |
| 9 | Lefoxin Tab. | Precautions for use | 2022.03.27 | PDFLevoxin tablet (levofloxacin hydrate)_Precautions for use.pdf |
| 8 | Lefoxin Tab. | Repoxin tablet (effectiveness, precautions for use) | 2020.04.21 | PDFPermission change order (draft)_Lepoxin tablet 100 mg.pdf |
| 7 | Lefoxin Tab. | Repoxin tablet (effectiveness, precautions for use) | 2016.12.06 | HWP45_Lepocsinjeong.hwp |
| 6 | Lefoxin Tab. | Repoxin Tablet (Precautions for use) | 2016.04.14 | HWP48_Lepocsinjeong.hwp |
| 5 | Lefoxin Tab. | Repoxin Tablet (Precautions for use) | 2014.07.29 | HWPPrecautions for use_Levofloxacin_1.hwp |
| 4 | Lefoxin Tab. | Repoxin Tablet (Precautions for use) | 2011.05.24 | HWPPrecautions for using Repoxin tablets.hwp |
| 3 | Lefoxin Tab. | Repoxin Tablet (efficacy, dosage, usage precautions... | 2008.01.02 | HWP9-3.Lepoxinjeong (2008.01.02).hwp |
| 2 | Lefoxin Tab. | Repoxin Tablet (Precautions for use) | 2009.09.07 | HWP9-2. Repoxin tablet (precautions for use) (2009.09.07).hwp |
| 1 | Lefoxin Tab. | Repoxin Tablet (Precautions for use) | 2009.10.07 | HWP9-1. Repoxin tablet (precautions for use) (2009.10.07).hwp |